FIGURE 1.

Exacerbation rates in the on‐treatment and on/off‐treatment (A) and subgroup (B) analyses, and the proportion of patients with an exacerbation in the on‐treatment and on/off‐treatment (C) and subgroup (D) analyses. The follow‐up period in the on‐treatment analysis was the time until 1‐year post‐mepolizumab initiation, discontinuation of mepolizumab, or treatment with another biologic or bronchial thermoplasty (whichever is earlier); the follow‐up period in the subgroup analysis was the same as on‐treatment analysis except included only those patients with ≥2 exacerbations during the baseline period and ≥10 mepolizumab administrations during the follow‐up period. CI, confidence interval; IRR, incidence rate ratio